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Ischemic stroke is one of the leading causes of brain injury and death. Many mechanisms 
underlying ischemia-induced neuronal death have been investigated. Dysregulation of brain iron 
homeostasis is one of these mechanisms. It is well known that accumulation of intercellular iron 
in the brain induces free radical production, lipid peroxidation, and DNA damage. The overall 
aim of this project was to investigate a novel therapeutic mechanism that could be targeted to 
reduce or prevent iron-induced ischemic brain injury. We hypothesize that heat shock protein 90 
(HSP90) plays a role in regulating intracellular iron accumulation upon ischemia and that 
inhibiting HSP90 rescues the brain from ischemic injury.  
First, in order to measure iron levels, the function of a newly developed hydroxylamine 
compound was tested as a ferrous ion probe. We found that this probe was able to indicate the 
level of ferrous ion both in cells and in solution with high sensitivity and reliability. Few 
interfering effects were observed by the presence of other metal ions and reducing agents on the 
iron measurement. KU32 is a HSP90 inhibitor that was used to investigate whether 
pharmacological inhibition of HSP90 reduced ischemic injury. We found that KU32 decreased 
levels of intercellular iron and expression of hepcidin, a central iron regulator. In addition, KU32 
reduced neuronal death following ischemia. Taken together, this project has found a new method 
for measuring ferrous iron levels and a possible link among heat shock proteins in cellular iron 
regulation. These data suggest that targeting HSP90 may be a potential therapeutic approach to 
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Chapter 1 Introduction 
1.1.  Stroke 
Stroke is a very serious disease affecting human health, and as the second leading cause of death 
and disability worldwide. According to epidemiological studies,  approximately 12% of deaths in 
western countries all caused by stroke
1
, and this proportion is up to 9% worldwide 
2
. In 2000s, 2-
4% of worldwide total health-care cost was spent on stroke, while in developed countries the 
percentage was higher, up to more than 4%
3
. The problem of disability-adjusted life years 
(DALYs) caused by stroke-related disability makes stroke rank as sixth among all the common 
causes of DALYs in 2002
4
. By 2030, this rank is estimated to be fourth in Western countries
5
. 
With the increase in the aging population, the risk of stroke in projected to increase.  
Stroke was defined by the World Health Organization as a "neurological deficit of 
cerebrovascular cause that persists beyond 24 hours or is interrupted by death within 24 hours"
6
. 
There are mainly two types of stroke, hemorrhagic and ischemic. The following sections will 
explain these stroke types in more details. 
1.1.1.  Hemorrhagic stroke 
Hemorrhagic stroke is caused by a blood vessel rupturing within or surrounding the skull cavity. 
With bleeding into the brain tissue or cranial vault, hematomas are formed and compress the 
brain tissue, which can lead to brain injury.  In addition, the elevated pressure in the skull can 
also limit the blood supply causing infarction. Furthermore, the blood irrigated in the brain has 
detrimental effects on brain tissue, in which inflammatory mediators, such as matrix 
2 
 
metalloproteinases (MMPs), nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase 
(HO), and iron toxicity plays a secondary role causing further brain damage
7
.  
1.1.2.  Ischemic stroke  
Ischemic stroke is caused by reduction of blood supply to the brain. There are four major reasons 
contributing to this pathological condition: (1) an obstruction in peripheral blood vessel forming 
by a blood clot (thrombosis), (2) an obstruction in peripheral blood vessel formed by an embolus 
(embolism)
3
, (3) a general decrease of blood supply (systemic hypoperfusion)
8
, (4) cerebral 
venous sinus thrombosis
9
. Heart failure is associated with about 9%
10
 of all strokes and is a 
major risk factor for ischemic strokes since it causes systemic hypoperfusion
10
. 
Due to the loss of blood supply in the brain, an ischemic cascade is initiated
11
. The loss of blood 
supply directly results in the deprivation of oxygen and nutrients, such as glucose, delivered to 
the brain. This restriction of oxygen and nutrients impairs the brain tissue functions within one to 
two minutes following the infarction. A long restriction of blood supply to the brain (> 3 hours) 
can cause irreversible tissue damage with a massive death of cells in the ischemic area. 
Glutamate plays an important role in the tissue injury during oxygen and glucose deprivation in 
stroke. In the absence of oxygen and glucose, low levels of ATPs are generated, resulting in 
reduction of the energy source for the ion pump which maintains concentration gradients of ions 
(mainly sodium) across the cell membrane. Downregualtion of  transmembrane ions may induce 
glutamate release into the extracellular area, activating numerous receptors, such as the N-
methyl-D-aspartate (NMDA) receptor which stimulates cellular influx of calcium
12
. This calcium 
influx activates the enzymes to digest the components of the cell, causing cell death. At same 






Reactive oxygen species (ROS),   such as oxygen free radicals are generated during ischemia. 
Prooxidant enzymes are involved in this production of oxidative stress, which could be divided 
into three major classes based on their products: (1) nitric oxide synthases (NOS), 
producing NO ∙; (2) cyclooxygenases (COX), xanthine dehydrogenase (XDH), xanthine oxidase 
(XO) and NADPH oxidase (NADPHO), producing O2 ∙
−; (3) myeloperoxidase (MPO) and 
monoamine oxidase (MAO), producing HOCl and H2O2, respectively
14
. It is well known that 
ROS oxidize and damage the macromolecular cell components, lipids, proteins and DNA, 
leading to cell death and brain injury
15-17
. Mitochondria, apurinic/apyrimidinic 
endonuclease/redox factor-1 (APE/Ref-1), a DNA repair enzyme, and transcription factors are 
reported to be the major targets of ROS that contribute to the cell death
18,19
. 
1.1.3.  Reperfusion injury 
The reperfusion following ischemia could exacerbate tissue damage and cause further necrosis, 
though the mechanism of ischemia/reperfusion injury is still far from being understood
20
. 
Although reperfusion gets the blood flow back to normal levels after ischemia, the injury 
unexpectedly turns out to be more serious. With some aspects still in debate, the mechanisms 
underlying reperfusion injury may include: (1) the increase of oxidative/nitrosative stress 
generated by refueling of oxygen and glucose along with the replenishment of blood; (2) calcium 
overload; (3) the opening of the mitochondrial permeability transition (MPT) pore; (4) 




The brain is the most susceptible organ to the ischemia reperfusion injury. This is because of the 
high demand and low store of energy resources, such as glucose
22,23
. In addition, the relatively 
4 
 
lower level of antioxidant, such as superoxide dismutase (SOD), catalase, glutathione 
peroxidase
24
 and heme oxygenase-1
25
 possessed by the brain is another contributes to the 
susceptibility of the brain to ischemia reperfusion. Furthermore, polyunsaturated fatty acids, one 
of the major energy resources in brain, are also vulnerable to oxidative stress
24
. Additionally, 
some neuro transmitters could induce calcium overload
22
, which is involved in inducing 
ischemia reperfusion injury in brain as well.  
1.2.  Iron regulation in central nervous system (CNS) 
Iron is an indispensable element for human body. It is widely known as a key component of 
hemoglobin, delivering oxygen throughout the whole body. In the central nervous system (CNS), 
iron also plays a key role in various metabolic regulations. Numerous studies have suggested that 
iron dysregulation is involved in most neurodegeneration diseases, such as Parkinson’s disease, 
amyotrophic lateral sclerosis and cognitive deficits
26-28
. Moreover, iron chelation is also being 





 and Friedreich’s ataxia
31
. Although mechanisms still remain 
unclear, iron accumulation is widely assumed to mediate free radical generation and enhancing 
oxidative stress, which contributes to cell death in the CNS
30,32
. 
1.2.1. Iron and ischemic stroke 
Several studies have reported that iron overload induces free radical production and cell death in 
stroke
34-36
. During ischemic stroke, the hypoxic condition induces iron to unbind from the iron-
storage proteins (i.e. ferritin). Ferric iron is released from ferritin and reduced into ferrous in the 
presence of ROS. In addition, the increased acidic level during hypoxia catalyzes the ferric iron 
releasing from transferrin. These series of reactions elevates the iron level in ischemic brain. 
5 
 
Disruption of iron homeostasis induces ischemic brain injuries
37,38
. The Haber–Weiss reaction 
catalyzes the conversion of superoxide (O2 ∙
−) to the highly reactive toxic hydroxyl free radicals 
(HO ∙)39,40, which is involved in tissue injury. 
O2 ∙
−+ H2O2  → HO ∙ +OH
− + O2 




−+ Fe3+  →  Fe2+ + O2 ;  Fe
2+ + H2O2  → Fe
3+ + HO ∙ +OH− 
These hydroxyl free radicals lead to apoptosis and cause tissue damage. In addition, iron can also 
cause lipid peroxidation
41




1.2.2. Iron transport in CNS 
Transferrin plays a major role in mediating iron entrance into endothelial cells from the 
blood
45,46
.  The divalent metal transporter 1 (DMT1) is involved in iron uptake by endothelial 
cells
47
 while ferroportin contributes to the iron export to the abluminal side of endothelium
47
. 
Astrocytes are involved in the release of iron from endothelium at the abluminal surface
48,49
. In 
the brain interstitium, iron mainly exists in the ferric state, binding to transferrin as well as 
molecules such as citrate, ATP, ascorbic acid
50
 and the protein lactoferrin
51
. Neurons express 
transferrin receptors and DMT1
52
 that the expression of transferrin receptors can be response to 
the neuronal iron levels
46, 53
. Some neurons also express ferritin which can store iron
54
. 
Ferroportin works as the iron exporter in neurons, which is an essential factor regulating 
neuronal iron level
55
. Hepcidin is an inhibitor of ferroportin. Astrocytes uptake non-transferrin 





. Oligodendrocytes also do not express transferrin receptors but have ferroportin
55,56
, so 
their iron uptake is similar to astrocytes and their export is by ferroportin. The major route of 




1.2.3. Iron regulatory proteins 
Numerous proteins are involved in iron regulation and the following section gives a brief 
introduction to some iron regulatory proteins involved in this research. 
Hepcidin 
Hepcidin is a hormone that plays a key role in iron regulation
58
 and is mainly synthesized by 
hepatocytes
59,60
. Bone morphogenetic protein (BMP) and JAK2/STAT3 signaling pathways can 
mediate hepcidin transcription. In addition, iron can also increase hepcidin expression under 
nonpathological conditions
58
. Ferroportin is the target of hepcidin. Hepcidin can bind to 




Ferroportin is a transmembrane protein that exports iron
62-64
. As a transporter, ferroportin 
mediates ferrous iron (Fe2+) efflux65,66. During cellular iron efflux, ferrous iron is oxidized into 
ferric iron by multicopper oxidases, either hephaestin or ceruloplasmin
67-69, 70
. Moreover, 
ferroportin is the receptor of hepcidin and can be inhibited by hepcidin.  
1.2.4. Distribution of iron regulatory proteins in CNS 
According to existing reports, tables of iron regulatory proteins in the CNS were made to 
indicate the expression of iron regulatory proteins. Table 1 shows the distribution of iron 
regulatory proteins among different types of cells. Neurons express numerous proteins regulating 
7 
 
iron homeostasis; the transferrin receptor and DMT1 mediate iron import, ferritin regulates to the 
labile iron pool and ferroportin mediates the iron export (Table 1). Ceruloplasmin is encoded by 
the CP gene
71-73
 and as a ferroxidase enzyme with 6 atoms of copper in its stucture
74
. With the 
copper dependent oxidative activity, ceruloplasmin induces the oxidation of iron(II) into iron(III) 
so that the iron ions can be carried by transferrin
75
. Lactoferrin is a multifunctional member of 
the transferrin family, also known as lactotransferrin
76
. Lactoferrin receptors mediate lactoferrin 
internalization and iron absorption.  
Glial cells, including astrocytes, oligodendrocytes and microglia, usually express part of these 
iron regulatory proteins, and all thought to play regulatory roles in maintaining iron homeostasis. 
Most glial cells do not express transferrin receptor and DMT1 while the expression of DMT1 in 
astrocytes is in debate, so glial cells lack the major method to internalize iron. However, the 
presence of lactoferrin receptors and ferritin as well as the expression of ferroportin in astrocytes 
suggests that glial cells have a capacity for iron transport, storage and export. In addition, based 
on the supporting functions of glial cells to neurons, glial cells might be involved in neuronal 
iron regulation. Moreover, in brain capillary endothelial cells, a major component of blood-brain 
barrier, most of the iron regulatory proteins also exist, which is consistent with the theory of iron 
transport across the blood-brain barrier. A major pathway of iron transport across the blood-brain 
barrier is via transferrin. However the other transporters such as, DMT1 and ferroportin are also 
involved. Generally, iron transport across the blood-brain barrier is similar to iron absorption in 
the intestines. Table 2 shows the distribution of iron regulatory proteins among different brain 
regions. Cerebral cortex and hippocampus have transferrin receptors to take iron into cells. 
However, there is no report showing any evidence about the expression of transferrin receptors 
in the corpus striatum. In addition, ferritin exists widely in different CNS components such as 
8 
 
cerebral cortex, hippocampus and corpus striatum as well as serum and cerebrospinal fluid, 
indicating that iron is stored widely throughout the brain. Also hepcidin is expressed widely, in 
cerebral cortex, hippocampus and corpus striatum, indicating that it is involved in iron regulation 
in the CNS. 
In summary, different iron regulatory proteins widely exist in different regions in the brain. 
These proteins all contribute to maintain iron homeostasis in the CNS, forming a complicated 
regulation network of iron transport and storage. However, there are still some blanks in these 
tables and expression of these proteins in specific brain regions are still in debate. Hence, more 
research is needed to improve our understanding of iron regulation in the CNS.   
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Table 2 Iron regulation in different brain regions 
Brain regions Transferrin receptor Ferritin Hepcidin 
Cerebral cortex +
106

















Serum   +
107,108
  
Cerebrospinal fluid  +
107
  
Note: +, expressed; -, unexpressed. L, ferritin light chain; H, ferritin heavy chain. 
1.2.5. Iron measurements 
Iron exists in its ionic forms. The following section discusses two probes applied in this research. 
Calcein-AM (calcein- acetoxymethyl ester) 
Calcein-AM is a well-established cytochemical method to measure the labile iron pool (LIP)
109-
112
. Calcein-AM is lipophilic, so that it can easily penetrate cell membranes, after which calcein-
AM is cleaved by cytosolic esterase inside the cells
113
. After the cleavage, calcein, one of the 
reaction products, quenches its green fluorescence after chelating iron in the cell. Other metal 
ions, such as Ca2+, Mg2+ and Cu2+, hardly affect either the fluorescence or the quenching110. 
Dequenching will happen after addition of a highly permeant iron chelator, by which the change 
in fluorescence gives a reliable estimation of iron level
114
. However, after the reaction of 
cleavage, calcein becomes hydrophilic and cannot penetrate membranes any more. Therefore, 





N-oxide chemistry could be applied to develop fluorescent probes in order to detect ferrous ion 
selectively. Since Nagasawa and coworkers developed the N-oxide probe, RhoNox-1, in 2012
115
, 
several hydroxylamine compounds have been developed. Within these compounds, the N-O 
bond is designed for ferrous ion to react with. After the reduction and cleavage of these N-O 
11 
 
bonds, fluorescence will be generated to mark the presence of iron (Scheme 1). For example, a 
kind of N-aryl-O-acylhydroxylamine is developed, and its fluorescence could be detected 
through microscopy
116
. In addition, this probe is sensitive and hardly affected by other metal 
ions
116
, such as Zn2+ and Cu2+. 
 
Scheme 1. The mechanism of ferrous ion inducing N-aryl-O-acylhydroxylamine to generate 
fluorescence 
1.3. Heat shock proteins (HSPs) 
Heat shock proteins (HSP) are a family of proteins usually produced by cells in response of 
stressful conditions such as heat shock, inflammation, starvation and hypoxia. The function of 
HSP is to stabilize new proteins and help to refold damaged proteins caused by cell stress
117-119
. 
1.3.1. HSP90 and HSP70 
HSP90 is a member of heat shock protein family and mediates the folding of numerous proteins 
into their final conformations. HSP90 can mediate tumor growth via vascular endothelial growth 
factor (VEGF) and nitric oxide synthase (NOS)
120
 and cancer metastasis through matrix 
metalloproteinase (MMP2) 
121
. HSP70 is also a member of heat shock protein family and has 
been reported as an important chaperone protein involved in oxidative stress and mitochondrial 











HSP90-dependent HSP70 upregulation to help to refold or clear aggregated and damaged 
proteins
122
. Moreover, upon the induction of HSP70, neuronal apoptosis and oxidative stress is 
often reduced
123,124
. According to recent research
125,126
, this HSP70 induction resulting from 
HSP90 inhibition has the potential to treat diabetic neuropathy and some neurodegenerative 
diseases. 
HSP90 has its ATPase activity due to its N-terminal and C-terminal DNA binding domains
127
. 
KU-32 (Figure 1) was develop as a C-terminal inhibitor of HSP90
128
. The inhibition of C- or N- 
terminals will abolish the ATPase activity and prevent protein folding
129
. In addition, HSP90 
also binds to heat shock factor 1, a transcription factor. The inhibition of HSP90 induces heat 
shock factor 1 dissociation from HSP90 and often its translocation to the nucleus, leads to the 




Figure 1. Structure of KU32 
1.3.2. Heat shock proteins and ischemia  
The function of HSP90 in the CNS under ischemia is complicated and the mechanism of HSP90 
in brain is not clear
130,131
. However, several studies have characterized a relationship between 
HSP90 and hypoxia induced factor-1 (HIF-1), an important transcription factor involved in 
ischemia. Some reports indicate that HSP90 can interact with hypoxia induced factor-1α (HIF-
1α) and stabilize it
132-134
. A recent study indicates that the interaction between HIF-1α and 
HSP90 is involved in the ability of N-acytlcysteine’s (NAC) to protect against stroke
135
. While 
HIF-1α is related to iron metabolism
136,137














. In addition, HIF-responsive elements (HRE) are located within the promoters of 
iron-related genes, such as the transferrin receptor (TfR) and heme oxygenase-1 (HO-1)
138
. 
Hence, there might be delicate mechanisms between heat shock proteins, HIFs and iron 
regulation in ischemia. 
1.4. This research 
In sum, ischemic stroke is a severe disease threating human lives, in which iron regulation and 
heat shock proteins might be involved. We established this research based on the hypothesis that 
inhibition of HSP90 reduces iron neurotoxicity and ischemia reperfusion injury in neurons. In 




Chapter 2 Materials and methods 
2.1. Materials 
Agents Catalog number Manufacture Address 
SH-SY5Y cell line CRL-2266 ATCC Manassas, VA 





FBS S11150 Atlanta Biologicals, Inc. Flowery Branch, GA 




Penicillin streptomycin P0781-100ML SIGMA-ALDRICH Milwaukee, WI 
Trypsin-EDTA SH30042.01 HyClone Laboratories, Inc. Logan, UT 
DMSO 34869-1L SIGMA-ALDRICH Milwaukee, WI 
Iron 307718-500G SIGMA-ALDRICH Milwaukee, WI 
Potassium chloride P217-500 Fisher Scientific Fair Lawn, NJ 
Calcium chloride 
dehydrate 
C3881-500G SIGMA-ALDRICH Milwaukee, WI 
Sodium chloride S271-3 Fisher Scientific Fair Lawn, NJ 
Lithium chloride L121-500 Fisher Scientific Fair Lawn, NJ 
Magnesium acetate 
tetrahydrate 
M566-50G SIGMA-ALDRICH Milwaukee, WI 
Zinc sulfate 8880 MALLINCKRODT, INC. St Louis, MO 
Cobalt chloride C371-100 Fisher Scientific Fair Lawn, NJ 
Sodium thiosulfate S-445 Fisher Scientific Fair Lawn, NJ 
Sodium sulfite S0505 SIGMA-ALDRICH Milwaukee, WI 
L-ascorbic acid A-4544 SIGMA-ALDRICH Milwaukee, WI 
Sodium metabisulfite 7777 MALLINCKRODT INC. St Louis, MO 
Deferoxamine D9533-1G SIGMA-ALDRICH Milwaukee, WI 
Calcein blue AM 564060 BD Biosciences San Diego, CA 
Dulbecco’s Modified 
Eagle’s medium 





Cocktail of protease 
inhibitors 
P-8340 SIGMA-ALDRICH Milwaukee, WI 
EDTA 1858567 Thermo Scientific Waltham, MA 
Bio-Rad DC protein 
assay agent 
 Bio-Rad laboratories, Inc. Richmond, CA 
HSP70 antibody ADI-SPA-810-D Enzo Life Sciences, Inc. Farmingdale, NY 
Goat anti-rabbit IgG-
HRP 
SC2030 Santa Cruz Biotechnology Dallas, TX 
Actin (I-19)-R SC-1616-R Santa Cruz Biotechnology Dallas, TX 
15 
 
Triton x-100 T8787-100ML SIGMA-ALDRICH Milwaukee, WI 
Poly-D-lysine P0899-10MG SIGMA-ALDRICH Milwaukee, WI 
2.2. Cell culture 
SH-SY5Y cells were cultured in DMEM/high glucose with 20% Opti-MEM, 10% FBS, 1x 
sodium pyruvate and penicillin streptomycin, at 37℃, 5% CO2, 95% air. Cells were trypsinized 
by trypsin-EDTA and subcultured from one passage to another. The drug treatment usually 
started when the cells were grown up to 70% confluence. Drug treatment usually lasted for 24 
hours. 
2.3. Iron measurement 
2.3.1. Hydroxylamine iron probe 
The new hydroxylamine iron probe was provided by Dr. Wei Wang and was dissolved in DMSO 
at 20mM and stored at −20℃. The storage vials and the box were also kept from light. The 
probe was diluted in cell growth medium, prior to use.  
In solution iron measurement 
Iron (II) was dissolved in distilled deionized water at concentration of 2mM. Other metal ion 
solutions were prepared at concentrations from 5mM to 100mM in distilled deionized water, 
K+ 100mM, Ca2+ 100mM, Na+ 100mM, Li+ 100mM, Mg2+ 100mM, Zn2+ 100mM, 
Co2+ 100mM, Cu+ 500μM (due to its low solubility), Cu2+ 100mM, in which chloride was 
applied as the negative counter ion. These solutions were diluted and added into 96-well plate to 
measure the fluorescence at excitation wavelength 500nm and emission 550nm. 
16 
 
In vitro iron measurement 
Cells were cultured in multi-well plates (6-well and 24-well) and treated with metal ions in 
growth medium for 24 hours after reaching 50% confluence. Fluorescent images were taken by 
microscope. Quantification of the fluorescence signal was done with ImageJ. Deferoxamine was 
used as iron chelator and served as a negative control. 
2.3.2. Calcein blue AM 
Calcein blue AM was dissolved in DMSO at 5mM and stored in the dark at−20℃. This stock 
solution was diluted into growth medium at a concentration of 5μM and added into the cell 
culture wells
139
. After one 5-minute incubation, the fluorescent images of cells were taken by 
microscope. The quantification of the fluorescence was done with help of the ImageJ. 
Deferoxamine was applied as iron chelator serving as a negative control. 
2.4. Ischemia/reperfusion model 
Oxygen and glucose deprivation (OGD) was used as an in vitro ischemia/reperfusion model. The 
hypoxia chamber can maintain an environment of 95% nitrogen and 5% carbon dioxide at 37℃. 
Cells were transferred into the hypoxia chamber and changed to OGD medium for 2 hours to 
mimic the ischemic process. The cells were then placed in normal medium without FBS, 
transferred back to non-hypoxic conditions and kept for 24 hours to mimic the reperfusion phase. 
After this series of treatment, the cells were collected for further experiments. 
2.5. MTT cell viability assay 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) solution was prepared at 
5mg/ml in PBS and was filtered through a 0.2μm filter. Cells were cultured in 96-well plate at a 
density of 10,000 cells/well. After treatment, 20μl of the MTT solution was added into each well. 
17 
 
The cells were incubated for 4 hours at 37℃ with 5% carbon dioxide, 95% air. The MTT 
solution was removed and replaced with 200μl of DMSO. The plate was further incubated for 
10-30 min, and the optical density of the wells was determined using the plate reader at 570nm 
and a reference wavelength of 630nm. 
2.6. Immunoblotting 
Proteins were extracted from SH-SY5Y cells by incubating the whole lysate with RIPA (Radio 
Immuno Precipitation Assay) buffer in the presence of a cocktail of protease inhibitors (Thermo, 
Meridian, IL) and EDTA. The protein concentration was determined by Bio-Rad DC protein 
assay reagent (Bio-Rad, Hercules, CA). Standard Western blot procedures
140
 were conducted by 
using primary antibodies against HSP70 and β-actin. The signal development was carried out 
with an enhanced chemiluminescence detection kit (Pierce, Rockford, IL). The intensity of 
immunoreactive bands was quantified using ImageJ. Results were normalized to β-actin
141
. 
2.7. In vitro immunocytochemistry 
Coverslips were coated with poly-L-lysine for 12 hours at room temperature. Sterile water was 
applied to rinse coverslips.  The coverslips were allowed to dry completely and sterilized under 
UV light. Cells were cultured on these coverslips and were treated at 80% confluence. After 
treatment, the coverslips were rinsed briefly in PBS, were fixed with methanol at room 
temperature (RT) for 20 min and the permeabilized with 0.3% Triton X-100 in PBS for 15min. 
To block nonspecific binding, cells were exposed to blocking solution (PBS containing 0.1% 
Triton X-100 and 1% BSA) for 30 min and incubated overnight at 4℃ with primary antibody. 
The cells were washed with PBST (PBS containing 0.1% Triton X-100) four times for 15 
minutes and incubated in secondary antibody for 90 minutes at room temperature in the dark. 
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After washing with PBST, the coverslips were mounted with Vectashield H1000 (temporary 
mounting medium, Vector Laboratories). The coverslips were sealed with nail polish. 
2.8. Statistical analysis 
Student t-test was applied to determine the significance differences between two groups of 
samples. One-way ANOVA was used to determine overall significance differences followed by 
post hoc Tukey’s test for multiple comparisons. Two-way ANOVA was used to determine the 
interaction between pretreatments and treatments. Data were presented as means ±SEM. 




Chapter 3 Results 
3.1. Iron measurement with hydroxylamine probe 
A newly developed hydroxylamine by Dr. Wei Wang’s lab was applied in this research to 
measure iron. The mechanism of this iron probe is that the iron (II)-dependent dehydroxylation 
of the hydroxylamine to the amine (Scheme 2). After cleavage of the N-O bond, the product, an 
electron-donating amine, has the feature to generate fluorescence. The intensity of fluorescence 
can indicate the level of ferrous. 
 
Scheme 2. The structure of hydroxylamine probe and it detection mechanism 
3.1.1. The fluorescence on different time points and concentrations 
The probe itself is non-fluorescent (𝜆𝑚𝑎𝑥,𝑒𝑚 = 556 𝑛𝑚, 𝜀 = 4800 𝑀
−1𝑐𝑚−1). In the presence of 
ferrous ion, fluorescence could be generated within 10 minutes (𝜆𝑚𝑎𝑥,𝑒𝑚 = 542 𝑛𝑚, 𝜀 =
55400 𝑀−1𝑐𝑚−1). Curves illustrating the different fluorescent intensities under different 
wavelengths were made (Figure 2Error! Reference source not found.), from which some 
information about the fluorescence wavelength of this probe could be read. Through these 
curves, the maximum fluorescent intensity was between 550nm and 600nm, approximately 
around 570nm. The fluorescence below 480nm and above 630nm was weak. Based on this result 
and information about this compound from Dr. Wei Wang’s group, we chose 𝜆𝑒𝑥 =
500 𝑛𝑚, 𝜆𝑒𝑚 = 556 𝑛𝑚 for later fluorescence detection in this research. In addition, time course 
20 
 
analyzes of fluorescent intensity (𝜆𝑚𝑎𝑥,𝑒𝑥 = 500 𝑛𝑚, 𝜆𝑚𝑎𝑥,𝑒𝑚 = 556 𝑛𝑚) (Figure 2B) was 
performed to define the reaction rate. During the first 10-20 minutes, the curve showed first 
order kinetics, meaning that during this period of time, hydroxylamine rapidly reacted with 
ferrous ion and generated fluorescence. After 20 minutes, rate of fluorescent increasing started to 
decrease, indicating zero order kinetics. Later, after 40 minutes, with the substrate depletion, the 
increasing of fluorescent intensity was very slow. And after about 2 hours had passed (Figure 
2C), the slope of the intensity curve of fluorescence was close to zero. These results demonstrate 
that the fluorescence generated from the reaction between ferrous iron and hydroxylamine probe 
is stable and able to last for more than 2 hours.  
Concentration-dependent experiments were performed to analyze the relation between 
fluorescent intensity and iron concentration. At first 3μM probe was added to ferrous solution at 
concentration ranging from 5μM to 25μM in 96-well plates, and the fluorescent intensity was 
measured by plate reader. Figure 2D shows that fluorescence was generated starting from 5μM 
iron. When the iron concentration went up from 5μM to 10μM, the fluorescence was 
significantly increased. And an increase in intensity occurred when the iron concentration was 
added up to 15μM. These results show that the intensity of fluorescence is positively correlated 
to the concentration of ferrous iron. However, the amount of increases in intensity between 5μM 
and 10μM was larger the increased amount between 10μM and 15μM. This suggests that the 
probe must be saturated at relatively higher iron concentration, and the saturation point is 
approximately at ratio 1 to 5-6 probe to ferrous ion. This was further substantiated by the 
fluorescent intensity at 20μM and 25μM of ferrous ion, between which no significant difference 
was found. Furthermore, 5μM probe was also used to detect the fluorescence difference on 
different concentrations, after which similar results were achieved. In the 5μM probe experiment 
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(Figure 2C), similarly, there was a significant difference in intensity between the 0μM ferrous 
ion group and 20μM group, but a much smaller difference between the 20μM group and 40μM 
group, and even no significant difference between 40μM and 80μM groups. On the other hand, 
this figure also shows that these differences are stable and able to last for more than 10 minutes. 
Similarly, this figure shows that the curve of fluorescence at 5μM ferrous ion is completely 
above the curve of 0μM group, indicating that the whole fluorescence generated by probe from 
wavelength 500nm to wavelength 600nm is completely enhanced by the presence of ferrous ion. 
In sum, these results indicate that this hydroxylamine probe possesses a time- and concentration-
dependent fluorescence, and that the maximum fluorescent intensity is around 570nm. 
Furthermore, these results suggest that in aqueous solution, this hydroxylamine probe is a potent 











Figure 2. Time and iron concentration dependent fluorescent intensity of the probe 
A. The fluorescence generated from the probe reacting with 0 and 5 μM iron under different 
wavelength of detection.  
B. The fluorescence generated from the probe at every minute from 8 to 74 minutes after the 
probe added into iron solution. 
C. The fluorescence generated from 5μM probe reacting with 0, 20, 40, 80μM iron 2 hours 
after the addition. This curve represents 10-minute detection. 
D. The fluorescence generated from 3μM probe and 5, 10, 15, 20, 25μM iron. 
The control solution of Figure A, B and D is dd water. The control solution of Figure C is 
5μM probe solution without ferrous ion. 
** 𝑝 < 0.01; 𝑛 = 8, Multiple comparisons among the 5, 10, 15, 20 and 25μM groups 
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3.1.2. The fluorescence on other agents 
Since iron can react with this hydroxylamine probe and generate fluorescence, in order to 
analyze its specificity to iron as a probe, other metal ions were also tested. In this research, 
several common metal salts were used to test the specificity of the probe. Potassium chloride, 
calcium chloride, sodium chloride, lithium chloride, magnesium acetate, cobalt chloride and zinc 
sulfate were applied to provide metal ions in solution. These ions have a relatively wide range of 
ion radius, with some of the ions (such as lithium ion) smaller than ferrous ion and some bigger. 
All these ions contain one or two charges, which is fairly common among metal ions. Also some 
of these metals are pretty close to iron in the periodic table, such as cobalt and zinc. More 
importantly, almost all of these metals have biological functions
142-149
. So testing of these metals 
on the probe will help to determine the potential biological specificity of this probe. On the other 
hand, negatively charged ions were not reactive, and did not influence the fluorescence 
significantly. 
Figure 3A shows the fluorescence generated by different metal ions. In this figure, except ferrous 
ion, all metal ions generate relatively low level of fluorescent intensities, even though their 
concentration is 19 times higher than the iron concentration. Among these metal ions, the 
fluorescent intensities did not have significant differences. In addition, except the cobalt ion, the 
other ions do not have color at that concentration (100μM); the slight red color of cobalt ion 
might have an effect on the fluorescence. More importantly, the red color of cobalt ion still did 
not have an obvious influence in fluorescent generation by the probe. 
Since iron has two forms of ions, ferrous and ferric, ferrous ion can lose one electron and turn 
into ferric ion. Hence, ferrous ion has reductive property. An assumption that the reductive 
property might be a sufficient condition of the fluorescence generation by the probe was raised. 
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So it is necessary to test the fluorescence generation on other reducing agents. Sodium 
thiosulfate, sodium sulfite, ascorbic acid, glutathione (GSH) and sodium metabisulfite was used 
as reducing agents. Among these reducing agents, sodium sulfite and sodium metabisulfite are 
mostly applied for industrial use
150
, while sodium thiosulfate has wide medical uses
151-154
 but 
seldom exists in human body. Ascorbic acid, also known as Vitamin C, has its own biological 
role as a highly effective antioxidant and electron donor in mammals
155
. GSH is also a major 
reductant in blood and cells with a concentration of 5-10mM. The tests of these reducing agents 
would help extend application of the hydroxylamine probe to industrial and biological regions. 
To avoid probe saturation, a relatively high concentration (50μM) of the probe was used. In 
Figure 3B, significant differences still existed between ferrous ion and other reducing agents, 
even though the concentration of the reducing agents is 9-39 times higher than ferrous ion. 
Relatively bigger differences also existed between different types of reducing agents, indicating 
that the fluorescent generation might depend on redox reaction and require reductive properties. 
But the rather significant difference between iron and these reducing agents still suggests the 
considerable specificity to iron (II) of this hydroxylamine probe. 
Though it has been found that the hydroxylamine probe has a higher specificity to iron than 
glutathione, there is still one point remaining to be clarified. The cellular concentration of 
glutathione is much higher than the concentration we used in our experiment. And it is still 
unclear whether the probe is able to react with ferrous first after entering the cell. 
In conclusion, neither metal ions nor reducing agents could make the probe generate 
fluorescence as potently as ferrous iron. In solution, this hydroxylamine probe has great 
sensitivity to react with ferrous iron. Even though the metal ions and reducing agents might 
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slightly be able to react with the probe, the rather weak intensity of fluorescence is unlikely to 





Figure 3. The fluorescence generated by metal ions and reducing agents  
A. This bar graph displays the fluorescence generated by the probe reacting with different 
metal ions. 
*** 𝑝 < 0.005, 𝑛 = 8, comparisons with 5μM ferrous ion 
B. This bar graph displays the fluorescence generated by the probe reacting with different 
reducing agents at different concentrations. The control group is untreated cells. 
*** 𝑝 < 0.005, 𝑛 = 8, comparisons with 10μM ferrous ion 
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3.1.3. Cellular iron measurement 
Iron levels were also measured by this hydroxylamine probe at the cellular level. After the cells 
were treated with iron for 24 hours, the intensity of fluorescence was measured by plate reader. 
Figure 4A is the graph made showing the fluorescence generated at different time points. In this 
figure, the shapes of the curves were similar to the one obtained in the solution-level iron 
measured by this probe.  During the first 20 minutes the intensity of fluorescence kept 
increasing, in zero order kinetics. At the period between 20 and 30 min the curve turned into first 
order kinetics. Then at about the point of 35min, the intensity of fluorescence started to decline at 
a slope lower than the increase period on curve. The decline implies that the probe might be 
degraded slowly in cells. The three lines in the graph from up to down represent 5μM iron, 0μM 
iron and 100μM DFO. The fluorescence of the cells treated with 100μM DFO was weak at first 
and disappeared within one hour (100μM DFO line in Figure 4A). Comparing these three lines, 
an increase of the intensity of fluorescence with the increase of the amount of iron treatment was 
showed. Through this figure, another conclusion can be made that in order to measure the 
cellular iron level through this probe the optimum time period for fluorescence detection locates 
at around 20-40 minutes after addition of the probe. And after 2 hours, the intensity of 
fluorescence will be too weak to detect. 
For further study, microscopy was used to detect fluorescence generation from the probe. This 
approach provides more information on the localization of the signals within the cells. Cultured 
cells were treated with different concentrations of iron for 24 hours before adding 5μM probe. 
After 15 minutes the cells were washed and observed under a fluorescence microscope. Figure 
4B shows the results of this microscope imagery study. According to these pictures, fluorescence 
increased with the augment of the concentration of iron treatment, while the blank group (no 
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probe used) did not generate any fluorescence. Quantification of the average intensity of each 
cell was made and all presented in the bar graph (Figure 4C). In the quantification, significant 
differences were seen between 10 and 20μM iron treatment, which was greater than the 
difference between 20 and 40μM. These data suggest that the probe reach the saturation point at 
the concentration of iron between 20 and 40μM. This saturation point was close to the results 
obtained in the solution-level of Figure 2. In addition, when the iron was chelated by DFO, the 
fluorescent intensity decreased significantly. These results indicate that this hydroxylamine 
probe can be used as a reasonable iron marker in cellular level studies. 
Next studies were processed to analyze the performance of the hydroxylamine probe in 
immunocytochemistry studies, a common and widely used study in molecular biology. During 
immunocytochemistry studies, proteins in cells are usually fixed and the cell membranes are 
permeated, which means the cells are dead and metabolism is stopped. After a 24-hour iron 
pretreatment of the SH-SY5Y cells, the cells were prepared following the same procedure as 
immunocytochemistry studies, fixed and permeated. Then 5μM probe was added to the cells, 
before the addition of DAPI as nuclear marker. After these treatments, the cells were observed 
under the microscope, as images of these cells captured. Figure 4D shows the results of this 
study. From this figure, green fluorescence generated from the probe and iron could be detected. 
There was no induction that the green fluorescence was affected by the nuclear stain. With the 
presence of iron chelator DFO, the intensity of the fluorescence was significantly decreased. 
Also the intensity of fluorescence was enhanced by iron treatment, which had a more directive 
presentation in the quantification graph, which quantified the intensity of the fluorescence and 
averaged to each cell (Figure 4E). Figure 4E shows a steady increase in intensity of the 
fluorescence with increasing iron concentration. DFO treatment abolished the fluorescence since 
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it is as the iron chelator. Slight recovering of the fluorescence appeared in Figure 4E in the 
groups with the combined treatment of DFO and iron. These results suggest that the probe is able 
to be applied in immunocytochemistry studies as an indicator of iron level. 
In sum, this group of studies has provided evidence supporting that this hydroxylamine probe is 
able to measure in iron in cells. The fluorescence generated by this probe is time and 
concentration dependent. In addition, the fluorescence is able to be detected by microscopically 
to get more information about iron inside cells. Furthermore, this hydroxylamine probe could be 

















Figure 4. The application of the probe in cellular iron measurement 
A. The graph shows the fluorescence generated by the probe inside SH-SY5Y cells at 
different time point after addition and different iron concentrations (0μM, 5μM and 
100μM DFO). n=4. The control group is the cells without treatment and probe. 
B. The images taken by microscope showing the fluorescence of the probe inside SH-SY5Y 
cells under different iron concentrations. 
C. The quantification of the intensities of the fluorescence in Figure B. n=4. The control 
group is untreated cells. 
D. The images taken by microscope showing the nucleus the fluorescence of the probe in 
fixed SH-SY5Y cells under different iron concentrations. 
E. The quantification of the intensities of the fluorescence in Figure D. n=4. The control 
group is untreated cells.  
* p<0.05, compared with non-treated (0) group 
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3.1.4. Effects of metal ions in cellular use of the probe 
In order to study the effects of metal ions on the probe measuring cellular iron levels, SH-SY5Y 
cells were treated for 24 hours 250μM calcium, lithium, magnesium, or 100μM zinc or 100μM 
cobalt. 5μM probe was added to the cells, and fluorescence was detected by a plate reader. A 
time and intensity of fluorescence curve was made to illustrate the fluorescence changes at 
different time points (Figure 5A). Based on the results of iron measurement by the probe inside 
cells, the time period between 20 and 30min was chosen to study the fluorescence generation 
under metal ions treatment. Figure 5A shows that the fluorescence did not change with time, 
while the intensity of the fluorescence was pretty low despite the high concentration of the metal 
ions. Figure 5B shows a comparison between iron and various metal ions in the intensity of 
fluorescence generated by the probe inside cells. This result shows that fairly small differences 
exist in intensity of fluorescence among the groups under different metal ion treatments, and 
generally all the fluorescence generated in these groups are weak even at high concentration. 
However, in the iron treatment group, even though the concentration of treatment was rather low, 
the intensity of fluorescence generated was relatively high compared to the metal ions. These 
results are consistent with the results from the in-solution study of the probe. 
The effects of metal ions on the fluorescence were also analyzed by microscopy. Cultured SH-
SY5Y cells were treated for 24 hours with high concentration of metal ions, 250μM potassium, 
calcium, sodium, lithium, magnesium, or 100μM zinc, 100μM cobalt. The probe was added to 
the cells 15 minutes before detection. Figure 5C shows the results of the microscopy. Though 
green fluorescence could be observed from the metal ions, the fluorescence is weak and more 
obscure compared with the iron treated group. Figure 5D shows the quantification of these 
results. Through this graph, a significant difference in the intensity of fluorescence between iron 
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treated group and other metal ions treated group is observed. However, within the metal ions 
treated groups, the intensities of fluorescence did not show much difference, and was generally 
very low. 
In summary, these studies provided evidence to support that the probe is not affected by metal 
ions except iron. Thus, the hydroxylamine probe is able to specifically indicate iron level even in 














Figure 5. The fluorescence generated by metal ions in cellular application of the probe 
A. The time-intensity curve shows the changes of fluorescence by calcium, lithium, 
magnesium, zinc and cobalt in cells during the period 20-30 minutes after the addition of 
probe. The control group is the cells without treatment and probe. 
B. The bar graph shows the different intensity of fluorescence by different metal ions in 
cells. The control group is the cells without treatment and probe. 
C. The images taken by microscope under GFP showing the fluorescence of the probe inside 
SH-SY5Y cells under different metal ions. 
D. The quantification of the intensities of the fluorescence in Figure C. 
* 𝑝 < 0.05, 𝑛 = 4, compared with ferrous ion 
3.1.5. The effects from cuprous and cupric ions to this hydroxylamine probe 
Copper is a metal element very close to iron in periodic table, which means that they have some 
similar physical and chemical properties, such as the similar size of copper and ions. In addition, 
copper also has two ionic forms copper (I) and copper (II), which means cuprous (copper (I)) ion 
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has a reductive property similar to ferrous iron. Moreover, copper is an important component 
involved in many biological reactions, which means copper widely exists in biological materials 
and might have an effect on the fluorescence of the probe. More importantly, copper was 
reported to affect an acetyl hydroxylamine probe more than other factors
116
. Hence, we examined 
the effects of copper on the hydroxylamine probe. First, the experiments were done in solution 
without cells with fluorescence measured by a plate reader. Figure 6A shows the curve of the 
fluorescence intensities at different time points during the first hour after addition of the probe. 
An increase in fluorescent intensity caused by cupric ion was observed during the first 50 
minutes after the addition of the probe. After about one hour, the fluorescence plateaued, 
meaning that the increase in fluorescence is almost stopped. On the other hand, the fluorescence 
generated by cuprous ion was relatively potent at the first 10 minutes and started to decline and 
disappear by 30min, which might because cuprous ions tend to precipitate due to their low 
solubility. However, even at 10-20 fold higher concentration than iron, the fluorescence 
generated by copper was still significantly weaker (Figure 6B and Figure 6C). Next, the study of 
this probe in cells also did not show a significant role of copper in fluorescence generation. In the 
time-intensity curve (Figure 6D), the fluorescence by both copper (I) and copper (II) had a 
latency in generation and declined very fast. The reason for this might be that the sensitivity of 
the probe to copper is low and the possible degradation mechanism of the probe in cells only 
provided a short period time when the concentration of probe is enough to react with copper. In 
addition, when the fluorescence reached into the highest point (about 35min), the intensity was 
still significantly lower than iron (Figure 6E). Figure 6F gives shows fluorescence images of the 
copper and iron reacting with the probe inside cells respectively. A bar graph indicates the 
quantification of the fluorescent intensity (Figure 6G). The fluorescence generated by copper 
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was also lower than iron, further supporting that copper does not have a potent effect to react 
with the probe. 
Taken together, both cuprous and cupric ion poorly reacts with this probe. The fluorescence 
generated by the reaction is weak, and not likely to disturb iron detection. With the relatively 
lower level of copper (I) and copper (II) in human body
156
, copper showed not be a factor that 



















Figure 6. Effects of cuprous and cupric ions on the hydroxylamine probe 
A. The intensity-time curve shows the fluorescence by the probe in iron or copper solutions. 
n=8 
B. The bar graph shows the fluorescent intensity of different solutions 8 minutes after the 
addition of probe. n=8 
C. The bar graph shows the fluorescent intensity of different solutions 72 minutes after the 
addition of probe. n=8 
D. The intensity-time curve shows the fluorescence by the probe reacting with iron or 
copper inside cells. n=4. The control group is the cells without treatment and probe. 
E. The bar graph shows the fluorescent intensity of different treatments to cells 40 minutes 
after the addition of probe. n=4. The control group is the cells without treatment and 
probe. 
F. The images taken by microscope show the fluorescence by the probe reacting with 
copper or iron inside cells. 
G. The bar graph shows the quantification of the fluorescent intensity of Figure F. 
* 𝑝 < 0.05, compared with treatment with iron 
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3.1.6. Summary of this hydroxylamine iron probe 
In conclusion, this hydroxylamine is a newly developed, reasonable ferrous iron probe. It has 
good specificity to react with ferrous iron and is hardly affected by other metals ions or reducing 
agents. The intensity of fluorescence generated by reaction between this compound and iron is 
positively correlated with the concentration of ferrous iron. The fluorescence generated by this 
probe can be detected by either plate reader or microscopy. This probe can be widely used both 
in-solution and in cells. 
In sum, this hydroxylamine compound is a powerful and reasonable ferrous probe and can be 
used as iron indicator in this research. 
3.2. Iron measurement via calcein blue AM 
Since the hydroxylamine probe can only detect ferrous ion, another iron probe is needed in this 
research to measure the total iron level. 
Calcein-AM is a well-developed dye to measure iron in live cells. The mechanism of iron 
measurement by calcein blue AM (Figure 7A), is similar to calcein AM, which has been 
mentioned above in the introduction. Calcein blue AM can cross the double layer lipid 
membrane and enter the cells, with the actoxyl methyl ester group removed, generating 
fluorescence, while the fluorescence will be quenched with the presence of iron (Figure 7B). One 
difference between calcein blue AM and calcein AM is the wavelength of detection (calcein blue 
AM: 𝜆𝑒𝑥 = 360 𝑛𝑚, 𝜆𝑒𝑚 = 445 𝑛𝑚). Some studies were done to confirm that calcein blue AM 
could be applied to measure ferric iron in our research. 
Figure 7A shows the structures of calcein blue and calcein. The structures indicate that calcein 
blue is a monomer of calcein, so they share properties in measuring iron. At first, an in-solution 
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calcein blue AM assay was performed, and the results show no difference among the groups with 
different treatments and different concentration of iron (Figure 7C). The reason is that the 
acetoxylmethyl ester group cannot be removed from calcein blue, resulting in no fluorescence 
generated. Calcein blue assay was also performed in cells with the fluorescence detected by plate 
reader. Cells were pretreated with different concentrations of iron, then 5μM calcein blue AM 
was added, after which the fluorescence was detected. This result shows a decrease in 
fluorescence intensity on the increase of iron concentration (Figure 7D).  This result does not 
show an obvious difference between 0 and 5μM iron treatment. The reason for this might be 
because the sensitivity of the plate reader or calcein blue, which resulted in unclear results under 
low iron concentration. The fluorescent quenching was rather clear under higher iron 
concentrations.  And the difference of fluorescent quenching between 20 and 40μM iron was 
approximately twice as big as the quenching difference between 10 and 20μM. In addition, 
microscope was used to observe the fluorescent quenching by iron. Figure 7E shows that as the 
concentration of iron treatment to the cells went up, the intensity of fluorescence went down. 
However, the DFO treatment significantly decreased the fluorescent quenching. A quantification 
of the fluorescent intensity per cell from the pictures taken by microscope was made (Figure 7F). 
This bar graph shows the ratio of the fluorescence to the 0μM iron treatment group, from which a 
more obvious decrease in fluorescence after the increase of iron level could be observed directly. 
Moreover, this bar graph also indicates the relation between iron level and fluorescence 
quenching is close to a linear correlation. 
All these studies above about calcein blue AM suggested that calcein blue AM is a reasonable 
iron probe and suitable for our research. The fluorescence of calcein blue can both be detected by 
plate reader and microscope. However, the requirement of live cells by calcein blue AM will 
42 
 
limit its application in iron measurement. And different types of cells and the cell metabolism 
might also have an effect on the calcein blue fluorescence generation. But as every coin has two 










































































Figure 7. Iron measurement by calcein blue AM 
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A. The structures of calcein AM and calcein blue AM are showed. 
B. Calcein AM is turned into calcein which can generate fluorescence by esterase. 
C. The bar graph shows the results of the application of calcein blue AM in iron solution. 
D. The bar graph shows the results of the application of calcein blue AM in cells after 
different concentrations of iron treatment. 
* 𝑝 < 0.05, 𝑛 = 8, comparison between 0 and 40μM iron 
E. The images taken by microscope under DAPI showing the fluorescence of the calcein 
blue inside SH-SY5Y cells under different iron concentrations. 
F. The quantification of the intensities of the fluorescence in Figure E. 
* 𝑝 < 0.05, 𝑛 = 4,  multiple comparisons among DFO, 0, 5 and 10μM iron 
3.3. The effect of KU32 on cell viability 
KU32 is an inhibitor of HSP90, which is a chaperone protein and involved numerous regulatory 
processes in the cell. To determine whether KU32 has an effect on cell viability during ischemia, 
two groups of SH-SY5Y cells were treated with KU32 (0μM, 2μM and 10μM) and then put into 
normoxic or OGD conditions for 2 hours. After the normoxia and OGD incubation, the MTT 
assay was used to determine cell viability under different conditions and concentrations of 
KU32. Figure 8B shows the results of the effect of KU32 under OGD condition. According to 
Figure 8B, the presence of KU32 did not significantly alter cell viability. In addition, under 
normoxia condition (Figure 8A), the cell viability hardly increased by using the MTT assay. 
These results indicated that KU32 might not have a potent effect on cell viability under ischemia 
(OGD) condition. The western blot data showed in Figure 8C also showed there was no 
significant change on the expression of HSP70, which has been showed to mediate some of the 
neuroprotective effects of KU32. 
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Based on the theory of reperfusion injury
20-23
, further experiments were designed to study the 
effects of KU32 treatment under ischemia and reperfusion condition. Two groups of SH-SY5Y 
cells were pretreated with KU32 for 24 hours and then transferred to normoxia or ischemia 
(OGD) condition, followed by a 24-hour reperfusion. After the ischemia/reperfusion, the MTT 
assay was performed. Figure 8D shows a significant increase in cell viability in the presence of 
4μM and10μM KU32. Consistent with the increase in cell viability, western blot analyzes show a 
significant increase in HSP70 expression by KU32.  
These results suggest that HSP90 inhibitor KU32 increases HSP70 expression and has a neuro-
protective effect to neurons under ischemia-reperfusion. This effect mainly happens during the 













Figure 8. Effects of KU32 on cell viability and heat shock proteins 
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A. This bar graph shows the cell viability of SH-SY5Y with the treatment of KU32 under 
normoxia condition. 
B. This bar graph shows the cell viability of SH-SY5Y with the treatment of KU32 under 
ischemia condition. n=8 
C. The western blot and quantification show the expression of HSP70 with the treatment of 
KU32 under ischemia condition. 
D. This bar graph shows the cell viability of SH-SY5Y with pretreatment and treatment of 
KU32 under ischemia reperfusion condition. n=7 
E. This western blot and quantification show the expression of HSP70 with pretreatment and 
treatment of KU32 under ischemia reperfusion condition. n=4 
 ∗ 𝑝 < 0.05, ∗∗  𝑝 < 0.01, ∗∗∗  𝑝 < 0.005; 𝑛 ≥ 3, compared with the non-treated group 
3.4. The effect of KU32 on iron levels under ischemia reperfusion 
Since a neuroprotective effect of KU32 during ischemia-reperfusion was observed and iron is 
widely reported as a factor inducing oxidative stress and cell apoptosis
37,38,41
, we hypothesized 
that inhibition of HSP90 by KU32 might change the iron level in neurons under ischemia-
reperfusion condition.  
SH-SY5Y cells were cultured in 6-well plates. After reaching 80% confluence, the cells were 
treated with KU32 for 24 hours, which was followed by 2-hour ischemia and 24-hour 
reperfusion. Then both calcein blue AM and the hydroxylamine probe were utilized to measure 
iron levels by fluorescence microscopy.  Figure 9A shows the distribution and level of iron 
inside cells under different conditions and KU32 treatments. Using calcein blue AM Figure 9B 
presents the quantification of the average fluorescence intensity. Under normoxia condition, the 
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two rows of images on the top of Figure 9A, the intensities of fluorescence from calcein blue did 
not show much difference with different concentrations of KU32. On the other hand, under 
ischemia condition, the two rows of images on the bottom of Figure 9A, a decrease of the 
intensities of fluorescence was detected comparing with the groups under normoxia, indicating 
an increase of iron occurred under ischemia. However, with the presence of KU32, the 
fluorescence of calcein blue was enhanced, suggesting the amount of iron inside cells was 
decreased by KU32. Figure 9B is a bar graph generated after the quantification of the intensities 
of fluorescence, giving a more direct presentation of these results. The newly developed 
hydroxylamine probe was also used in this study to indicate iron level. Figure 9C shows the 
results of iron level in cells under ischemia reperfusion, in which the green fluorescence 
represents the level of iron. According to Figure 9C and the quantification of the intensity of 
fluorescence (Figure 9C), the iron level was deceased with the increase of the concentrations of 
KU32 treatment, which is consistent with the results obtained with calcein blue AM. 
Overall, this group of experiments suggests that the inhibition of HSP90 by KU32 has a negative 
effect on iron accumulation in SH-SY5Y cells during ischemia-reperfusion. This effect on iron 













Figure 9. Effects of KU32 on the iron level in SH-SY5Y cells exposed to ischemia-
reperfusion 
A. The images taken by microscope under DAPI showing the fluorescence of calcein blue 
inside SH-SY5Y cells with the treatment of KU32. 
B. The quantification of the intensities of the fluorescence in Figure A. The control group is 
the untreated cell under normoxia. 
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C. The images taken by microscope under GFP showing the fluorescence of the probe inside 
SH-SY5Y cells with the treatment of KU32 under ischemia reperfusion. 
D. The quantification of the intensities of the fluorescence in Figure C. The control group is 
the untreated cell under normoxia. 
* p<0.05, n=4, comparison between 0 and 10μM KU32 
3.5. The effect of KU32 on hepcidin under ischemia 
Iron homeostasis is closely regulated by iron regulatory proteins. Since the inhibition of HSP90 
by KU32 decreases cellular iron levels during ischemia-reperfusion, there may be a relation 
between the KU32 treatment and iron regulatory proteins. A hypothesis was raised that the 




SH-SY5Y cells were cultured on coated coverslips. After reaching 80% confluence, the cells 
were treated with KU32 for 24 hours, which was followed by 2-hour ischemia and 24-hour 
reperfusion. Then specific antibodies were used to detect the amount and distribution of 
hepcidin. The images and the quantification of the intensities of fluorescence are showed in 
Figures 10A and B. Through the images and the quantification, an increase in the expression in 
hepcidin occurred under ischemia condition comparing with the normoxia groups, which could 
support the theory that cellular iron level is increased during ischemia. Moreover, under 
normoxia condition, the expression of hepcidin did not change with different concentrations of 
KU32 treatment, while under the ischemia conditions treatment of KU32 did make a reduction of 
the expression of hepcidin, especially at higher concentration. Lower hepcidin levels mean 
higher activity of ferroportin resulting in more iron exportation, which contributes to lower level 
52 
 
of cellular iron. Hence, these results are support the findings that the KU32 treatment can reduce 
cellular iron level during ischemia. 
In conclusion, this study of the role of HSP90 inhibition by KU32 on the expression of hepcidin 
implies that KU32 treatment is able to negatively influence the expression of hepcidin during 
ischemia-reperfusion injury, which might be related to the effects of KU32 on cellular iron 





Figure 10. Effects of KU32 on iron level in SH-SY5Y cells under ischemia-reperfusion 
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A. The images taken by microscope under TXRD showing the expression of hepcidin inside 
SH-SY5Y cells with the treatment of KU32 under ischemia reperfusion. 
B. The bar graph shows quantification of the intensities of the fluorescence in Figure A. The 
control group is the untreated cell under normoxia.  
* p<0.05, n=3, comparison between 0 and 10μM KU32 
3.6. The neuro-protective activity of KU32, iron level and hepcidin 
3.6.1. The relation between the effects of KU32 on iron and its neuro-protective 
activity 
Since KU32 treatment was neuroprotective and able to down regulate cellular iron level, it is 
necessary to determine whether there are any relations between them. In order to clarify this 
hypothesis, 200μM deferoxamine (DFO) was used to chelate iron in order to exclude the iron 
activities. After SH-SY5Y cells reached 90% confluence in the 96-well cell culture plate, DFO 
as well as KU32 was added to the cell culture medium 24 hours before the 2-hour ischemia 
incubation and the 24-hour reperfusion. A MTT assay was performed to test cell viability under 
the different treatments. Figure 11 shows the results of the MTT cell viability assay. According 
to these results, normoxia groups (Figure 11A) did not show a significant difference among 
either the groups treated with KU32 or the groups treated with both KU32 and DFO. However, 
in the ischemia (OGD) groups, the KU32 treatment showed a neuroprotective effect (Figure 
11B). However, with the cellular iron chelated by DFO, the addition of KU32 did not further 
increase the cell viability in ischemia-reperfusion. However, a difference existed between the 
non-treated group and DFO alone treated group, showing the protective of DFO. But with the 
increase of the level of KU32 treatment, no further increase in cell viability was showed. It 
indicates that the neuroprotection of KU32 was decreased with iron chelation. A two-way 
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ANOVA (Figure 11B) revealed a highly possible interaction between the treatment of KU32 and 
treatment of DFO, which suggests a relation between the iron chelation by DFO and the 
neuroprotective effect of KU32. This result provides indirect evidence that iron chelation 
prevents the neuroprotective activity of KU32. In fact, DFO has proved beneficial in ischemic 
brains. In our results, the cell viability with DFO treatment is higher than the control group. 
Hence, in Figure 11B, iron chelation by DFO reduced the neuroprotective effects of KU32. 
Taken together, it is possible that these results suggest that iron regulation is related to the neuro-
protective activity of KU32. 
In conclusion, these results suggest that the effect on iron regulation made by KU32 during 








Figure 11. Effects of KU32 on iron cell survival 
A. This bar graph shows the cell viability with the treatment of KU32 and combined 
treatment with both KU32 and DFO under normoxia. The control group is the untreated 
cells. 
B. This bar graph shows the cell viability with the treatment of KU32 and combined 
treatment with both KU32 and DFO under ischemia-reperfusion condition. The control 
group is the untreated cells. 
∗  𝑝 < 0.05, 𝑛 = 4, Multiple comparisons among the 0, 4 and 10μM groups 
^ 𝑝 < 0.05, 𝑛 = 4, comparisons between non-DFO pretreated group and DFO pretreated 
group 
# 𝐹(1, 2) = 4.87, 𝑝 < 0.05, two-way ANOVA revealed an interaction between treatment of 
KU32 and treatment of DFO. 
56 
 
3.6.2. The relation between the effects of KU32 on hepcidin and its neuro-protective 
activity 
A treatment with KU32 was neuroprotective and correlated with the down regulation of hepcidin 
expression during ischemia reperfusion, it is necessary to find out whether there is any relation 
between the neuroprotection and hepcidin.  
Fursultiamine can bind to ferroportin, the receptor of hepcidin. This disturbs the interaction 
between hepcidin and ferroportin and antagonizes the role of hepcidin in iron regulation
158
. 
Hence, 20μM fursultiamine was used in this study as the hepcidin antagonist to exclude the 
actions of hepcidin. After SH-SY5Y cell reached 90% confluence in the 96-well cell culture 
plate, fursultiamine as well as KU32 was added to the cell culture medium 24 hours before the 2-
hour ischemia incubation and the 24-hour reperfusion. An MTT assay was performed to test cell 
viability under different treatments. Figure 12 shows the results of the MTT cell viability assay. 
According to these results, normoxia groups did not show significant difference among either the 
groups treated with KU32 only or the groups treated with both KU32 and fursultiamine, slight 
decreases occurred with the presence of fursultiamine (Figure 12A). However, in the ischemia 
(OGD) groups (Figure 12B), the KU32 treatment showed its neuroprotective activities, KU32 
plus fursultiamine did not show a significant difference among the groups, with a two-way 
ANOVA showing an interaction between KU32 and fursultiamine, indicating that fursultiamine 
might block the neuro-protective activity of KU32 by acting as a hepcidin antagonist. Similarly, 
difference between the control group and fursultiamine alone treated group shows the protective 
of fursultiamine. But with the increase of the level of KU32 treatment, no further increase in cell 
viability was showed among the groups with both fursultiamine and KU32 treatment. It indicates 
that the neuroprotection of KU32 was decreased with the function of hepcidin disrupted. This 
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result suggests that it is possible that the interrupting the function of hepcidin in iron export 
might reduce the neuroprotective effect of KU32. These results could be a clue indicating that 
hepcidin also is involved in the neuroprotectivity of KU32. 
In conclusion, these results suggest that the effect on the expression of hepcidin made by KU32 
during ischemia reperfusion is related to the neuroprotection of KU32 and is possible to 





Figure 12. The effects of KU32 on hepcidin cell survival 
A. This bar graph shows the cell viability with the treatment of KU32 or combined treatment 




B. This bar graph shows the cell viability with the treatment of KU32 or combined treatment 
of KU32 and fursultiamine under ischemia reperfusion. The vertical axis shows the folds 
of cell viabilities to the control group under normoxia (Figure A). 
∗ 𝑝 < 0.05, 𝑛 = 7, Multiple comparisons among the 0, 4 and 10μM groups 
^ 𝑝 < 0.05, 𝑛 = 4, comparisons between non-fursultiamine pretreated group and 
fursultiamine pretreated group 
# 𝐹(1, 2) = 13.21, 𝑝 < 0.05, two-way ANOVA revealed an interaction between treatment 
of KU32 and treatment of fursultiamine. 
3.6.3. The neuro-protective activity of KU32, iron level and hepcidin 
Since the relation between KU32 on iron level and neuro-protective activity as well as the 
relation between KU32 on hepcidin and neuro-protective activity has been supported by the 
evidence above, a further experiment with both DFO and fursultiamine was performed to 
confirm the relation among neuroprotective effect of KU32, hepcidin and iron level. The results 
showed in Figure 13 are pretty similar to the ones above, that no significant difference occurred 
under normoxia, and the increase in cell viability by KU32 is prevented by the addition of iron 
chelator and fursultiamine, showing a relatively higher level of cell viability with smaller 
differences. Also the combined treatment increased the cell viability without KU32. In the 
groups with 10μM KU32 plus DFO and fursultiamine, the cell viability is also lower than the 
10μM KU32 group. A two-way ANOVA was also done and shows a highly possible interaction 
between the treatment of KU32 and the combined pretreatment DFO and fursultiamine in cell 
viability under ischemia-reperfusion. Similar to the results above, this result provides a 







Figure 13. The neuro-protective activity of KU32, iron level and hepcidin 
A. This bar graph shows the cell viability with the treatment of KU32 or combined treatment 
of KU32, DFO and fursultiamine under normoxia. 
B. This bar graph shows the cell viability with the treatment of KU32 or combined treatment 
of KU32, DFO and fursultiamine under ischemia reperfusion. The vertical axis shows the 
folds of cell viabilities to the control group under normoxia (Figure A). 
∗ 𝑝 < 0.05, 𝑛 = 10, multiple comparisons among the 0, 4 and 10μM groups 
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^ 𝑝 < 0.05, 𝑛 = 4, comparisons between non-DFO-fursultiamine pretreated group and DFO-
fursultiamine pretreated group 
# 𝐹(1, 2) = 4.31, 𝑝 < 0.05, two-way ANOVA revealed an interaction between treatment of 
KU32 and treatment of combination of DFO and fursultiamine. 
All these results suggest the relation between the neuro-protective activity of KU32 and the 
effect of KU32 on iron levels and hepcidin expression. Based on this study, we can conclude that 
the inhibition of HSP90 by KU32 might have a neuroprotective effect during ischemia 
reperfusion, which is related to the decrease of cellular iron level that possibly caused by the 




Chapter 4 Discussions and future directions 
 
Iron homeostasis plays an essential role in the health of CNS
26-28
, especially with regards to free 
radical generation and enhancing oxidative stress
30,32
. A general study of literature about iron 
regulation within CNS is necessary to form a basic understanding of iron regulation. Table 1 and 
Table 2 show the distribution of iron regulatory proteins in central nervous system. In general, 
neurons are well studied and a brief map of the iron transport in neurons has been established. In 
neurons, transferrin with iron is taken up by the transferrin receptor and after endocytosis, the 
iron is released and enters the cytosol through DMT1, forming labile iron pool that binds with 
ferritin, which is exported by ferroportin
159
.  On the other hand, all of these proteins do not 
necessarily exist in the other types of cells, such as glia and endothelial cells, suggesting that 
these types of cells may assist in neuronal iron regulation. Moreover, table 2 also tells that 
hepcidin is widely expressed throughout different brain regions, suggesting a key role of 
hepcidin in iron regulation in brain. However, these two tables are not able to cover all the 
information related to iron regulation proteins in CNS. There are still some debatable points, 
such as whether DMT1 and ferroportin are present in brain capillary endothelial cells. It is 
unidentified whether other types of cells in CNS share the same pathways of iron regulation with 
neuron or whether glial and endothelial cells have their own pathways regulating iron. Some 
proteins related to iron regulation are not listed in these tables, such as hephaestin
160,161
. In sum, 
iron regulation in the CNS is complicated and more research is needed to establish a 




After the review of iron expression in brain, several studies on iron were performed. According 
to the Fenton reaction
39,40
, ferrous iron is one of the most dangerous forms, but its measurement 
is not easy. Hence, studies to test a newly developed hydroxylamine iron probe were performed. 
In order to test the properties of fluorescence of the hydroxylamine probe, in-solution 
experiments were performed, getting the intensity-time, intensity-wavelength and intensity-
concentration graphs. Through these graphs, the properties of the fluorescence generated by the 
probe were determined. The 𝜆𝑒𝑚,𝑚𝑎𝑥 is close to 570nm. The intensity of fluorescence increases 
during an hour and the time point for reasonable detection was 40 minutes. Fluorescence has a 
linear relation with ferrous ion concentration. The 𝜆𝑒𝑚,𝑚𝑎𝑥 from our research is a little different 
from the one reported by Dr. Wei Wang’s group which is 556nm. The reason might be due to the 
different fluorometers. Besides, according to the intensity-wavelength curve, 15nm difference in 
wavelength around 560nm does not show much difference in intensity. All these results support 
the efficacy of this probe in measuring iron level in solution. 
Several factors that might affect the fluorescence of the probe in iron detection were tested
116
. 
Both metal ions and reducing agents were used in these duties, and no significant effects on the 
fluorescent generation from these ions and agents were found, implying high specificity of this 
probe to ferrous iron. 
One weakness of our results is about the glutathione reacting with the hydroxylamine probe, 
even though it has been found that the probe has higher specificity to ferrous than glutathione. 
The concentration of glutathione we chose is much lower than the concentration of glutathione in 
cells. That experiment was not well designed to mimic the biological conditions. Now it still 
leaves blank how the probe reacts in the condition of ferrous and much higher level of 
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glutathione. It is not determined whether the probe can react with ferrous properly with rather 
larger amount of glutathione (up to5 mM in cells). Even though our cellular studies showing a 
positive correlation between ferrous and fluorescence have provided possibilities that glutathione 
might not have a strong effect on the ferrous detection by the probe in cells, direct evidence is 
still missing to prove whether the effects of glutathione on iron measure by the probe can be 
neglected. 
Additionally, hydroxylamine groups have been found that they can react with aldehyde or 
ketone. But in our study, neither aldehyde nor ketone was used to test the probe. It is still 
unknown whether the presence of aldehyde or ketone has an effect on the iron detection of the 
probe. This aspect is also a weakness in our research. 
Cellular-level studies on the efficacy of this probe were also performed. After the addition of 
probe, the fluorescence generated by this probe reached a maximum at around 20 minutes after 
addition and slowly declined over 35 minutes. These kinetic properties showed a little difference 
from the in-solution studies. One possible explanation is that the cells might have degraded the 
probe. The degradation by cells starts when the probe enters the cells and its rate is related to the 
concentration of the probe inside the cells. When the rate of degradation goes up and equal to the 
rate of the probe entering and reacting with ferrous ions, the fluorescence reaches the maximum. 
This assumption can also explain why the fluorescence reaches maximum in cells earlier than in 
solution and the decline of the fluorescence in cells. The results also show that the in-cell use of 
this probe is able to be detected by fluorescent microscope. Quantification of the fluorescence in 
the images also showed a linear relation between ferrous concentration and intensity. On the 
other hand, the effects of other metal ions on the fluorescence generation were without any 
considerable effect. The fluorescence generated by non-iron metal ions and the probe is weak 
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and hardly detectable by microscopy. Furthermore, the application of this probe can also extend 
to dead cells, such as in immunocytochemistry. All the studies done on this hydroxylamine probe 
suggested that it is a reasonable and reliable iron probe and could be utilized in our further study. 
As a major iron probe currently in wide use, calcein blue AM was also tested to identify its 
efficacy to measure iron. Calcein blue showed a decent quenching in fluorescence in the 
presence of iron, and this loss of fluorescent intensity could be detected both by a plate reader 
and by microscopy. According to the quantification, the quenching of fluorescence correlated 
with the concentration of iron, indicating that calcein blue AM is a decent iron probe that is 
compatible with our research model. Furthermore, unlike the hydroxylamine iron probe, the 
detection of calcein blue AM is not limited to the ferrous iron, while ferric iron can also cause a 
decent quenching in the fluorescence of calcein blue, which can surely extend the application of 
calcein blue AM. However, the requirement of using live cells with calcein blue AM was also 
confirmed by our results, which means calcein blue AM is not able to be used in solution assay 
and more importantly calcein blue AM is theoretically not likely able to be used in 
immunocytochemistry studies. The reason for needing live cells to use calcein blue AM is that 
the cleavage between calcein blue group and AM group which is the prerequisite process for 
fluorescence generation is enzyme dependent. Interestingly, this property ensures another major 
application of calcein blue AM as a cell viability marker in flow cytometry. Generally, calcein 
blue AM is a reasonable iron probe and compatible with our research model, so that it can be 
used in our studies. 
As for the comparison between the two probes in this research, calcein blue AM and 
hydroxylamine probe, two points have been already mentioned above that calcein blue AM 
requires live cells but the hydroxylamine probe does not. Second calcein blue AM can detect 
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both ferrous and ferric iron while the hydroxylamine probe can only detect ferrous iron. In 
addition, another important point is that the hydroxylamine probe is an “off-on” fluorescent 
probe, which means the fluorescent intensity is positively correlated to the iron level, and has a 
relatively higher sensitivity than calcein blue AM. Hence, we can conclude that this 
hydroxylamine compound is an efficient and reasonable iron probe with high sensitivity.  
As an inhibitor of heat shock protein 90, KU32 enhanced cell viability under ischemia-
reperfusion conditions in SH-SY5Y cells. The inhibition to HSP90 by KU32 was confirmed by 
western blot showing an up regulation of HSP70. Furthermore, treatment with KU32 was also 
correlated with a down regulation the cellular iron level under ischemia-reperfusion. 
Additionally the expression of hepcidin was also decreased by treatment with KU32. Further 
experiments found that the effect of KU32 in enhancing cell viability under ischemia reperfusion 
was diminished by the iron chelator deferoxamine, the hepcidin antagonist fursultiamine and the 
combination of deferoxamine and fursultiamine. 
In general, these results show that KU32 has an inhibitory effect on heat shock protein 90 and a 
neuroprotective effect in SH-SY5Y cells under ischemia-reperfusion. Condition neuro-protective 
effect depends on the downregulation of hepcidin and a decrease in iron levels. These results 
provide a clue that KU32 might have a therapeutic effect on ischemic stroke, which might set up 
a new way in the therapy to ischemic stroke. Also these results put some light on the relation 
between heat shock protein inhibition and iron regulation, which might lead new discoveries into 
heat shock proteins regulation of iron homeostasis. Before this research, few studies analyzed the 
relation between heat shock proteins and iron regulation, which means that these findings are 
new in the area of iron and HSP studies. In sum, our findings suggest that KU32 leads to a 
possible new route to regulate hepcidin expression and cellular iron level, which might help cells 
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to survive under ischemia reperfusion conditions. Generally, a possible new route helping cell 
survive has been found and this route is related to heat shock protein and iron regulation.  
In specific, these results suggest heat shock protein 90 regulates the expression of hepcidin, 
which is an inhibitor of the iron exporter, ferroportin. That means the KU32 contributes to the 
cellular iron export in ischemia-reperfusion, which plays a role in enhancing cell viability. This 
pathway is able to explain all the results obtained in our studies. However, there are still several 
points about this regulation pathway remaining unidentified. Because of the inhibitory role of 
KU32, the amount of HSP90 is actually not changed with the presence of KU32. So the 
downstream factor of HSP90, HSP70 was chosen to indicate the activity of HSP90. So it is 
necessary to add direct evidence that the function of HSP90 was inhibited by KU32. Otherwise, 
there is the possibility that KU32 might increase the level of HSP70 directly. More importantly, 
since the level of HSP70 was chosen to indicate the activity of HSP90, and HSP70 also plays 
considerable roles in different pathways, it is also highly likely that HSP70 mediates the changes 
in the expression of hepcidin and iron regulation. In other words, HSP70 was involved in this 
research with its roles still being unidentified. Moreover, the link between heat shock proteins 
and iron regulation is weakly supported by our results, where considerable questions could be 
raised. For example, whether the iron level is moderated by HSP90, HSP70 or KU32 itself still 
remains unclear, and also what factors make the direct contribution to the down regulation of 
hepcidin remains unidentified. On the other hand, iron regulation is complicated and regulated 
by many factors. Based on our results, a conclusion cannot be made, that all of the other iron 
regulatory proteins are not involved in this process. However, on the contrary, it is highly 
possible that more than one iron regulatory proteins, such as transferrin and ferritin, are involved 
in this process after the treatment of KU32. Furthermore, there is no direct evidence that the 
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downregulation of cellular iron level has a cell protective effect. Hence, in order to fully prove 
this regulatory pathway, all of the questions raised above should be studied.  
In order to link the neuroprotective effect of KU32 and the functions in iron regulation of KU32, 
our results show that KU32 alone was able to increase cell viability, and when the iron was 
chelated or hepcidin was disrupt, the addition of KU32 cannot increase cell viability. Though the 
two-way ANOVAs in these results indicate that it is possible that iron regulation is involved in 
the neuroprotective effects of KU32, the cause and effect relation between neuroprotection and 
iron downregulation by KU32 cannot be surely established. Because some factors, such as 
ferroportin, involved in this process were not tested in our studies, we cannot certainly conclude 
that the neuroprotection of KU32 depends on iron regulation. More evidence should be added to 
support this pathway. Since downregulation of hepcidin can induce iron export, the upregulation 
of ferroportin and more iron released from cells by treatment of KU32 can be evidence to 
support the relation between KU32’s neuroprotection and downregulation of iron. Moreover, 
since iron overload can produce free radicals in cells, the downregulation of free radicals by 
KU32 treatment can also be evidence to support the relation. In addition, knocking down or 
inhibiting ferroportin can be an approach to further confirm the relation between the KU32’s 
neuroprotection and iron downregulation. On the other hand, we did not test if the drugs (KU32, 
DFO and fursultiamine) can react with each other in our research model, so it is also possible 
that the decreasing of neuroprotection is due to the interaction between drugs but not iron 
regulation. In sum, our result about KU32’s neuroprotection and iron downregulation proved an 
interaction between the treatment with KU32 and iron regulation in cell viability under ischemia-
reperfusion, which can be a clue indicating that the neuroprotection and iron downregulation 
links to each other. Numerous further studies are necessary to confirm the whole pathway and 
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cause effect relations of the neuroprotective and iron-regulative effects of HSP90 inhibition by 
KU32. 
In addition to the questions listed above, there is also something needed to clarify in this research 
on KU32 functions. First, and the most important, KU32 actually did not showed a huge neuro-
protective effect on the SH-SY5Y cell line, though the difference in cell viability by KU32 
treatment was significant. Several reasons might explain to this issue. The MTT assay was the 
only cell viability assay used, and some oxidative materials might have been released after the 
death of the cells during ischemia-reperfusion, which might cause false positive results by dead 
cells in MTT assay. In addition, the immunochemistry approach we used is not a perfect method 
to analyze hepcidin level. As a result of the small size of hepcidin (2.5kDa), it is difficult to find 
a both sensitive and accurate method to measure its level. Due to the relatively low accuracy of 
immunostaining, the standard error of the results was high and the difference between the groups 
was not very obvious. This weakness reduces the persuasiveness of our conclusions. If possible, 
more method should be added in determine the level of hepcidin, such as Tricine-SDS-PAGE, 
ELISA and real time PCR. Moreover, another type of the inhibitor of HSP90, iron chelator and 
hepcidin antagonist, might be used to increase the reliability of the results and conclusions. 
In summary, though there are some weaknesses and some areas needed to be further proved, a 
conclusion can still be presented that treatment with KU32 before and during ischemia-
reperfusion plays a role in decreasing hepcidin expression and cellular iron homeostasis and 




Iron is an essential element in human body and its homeostasis is regulated by numerous iron 
regulatory proteins. In the CNS, the distribution and expression of these proteins are not clear. In 
the future, one long-term goal is to establish a detailed iron regulation model to analyze the iron 
regulation and its roles in neurodegenerative diseases. Additionally, improving our 
understanding of the role of glial cells in iron regulation in the CNS could be another direction of 
future studies. Another area is to focus on the iron transportation and regulation across the blood 
brain barrier, since iron transported across the blood brain barrier is a major source of iron in the 
CNS.  
As for the iron probe, there are also various studies to do in future. First, further research is 
necessary to determine whether the high level of glutathione in cells can have a strong interfere 
to probe in iron measure. And more studies analyzing the mechanism of the chemical reactions 
between glutathione and the probe should be performed, in order to obtain a better understanding 
of the possible interfering effects of glutathione. Moreover, it is also necessary to determine 
whether aldehyde and ketone can react with the probe in solutions and cells. Since the probe 
specifically reacts with ferrous iron, its application is limited more or less. So to develop a probe 
that can detect both ferrous and ferric iron will be greatly helpful for biological iron study. In 
addition, according to the results of this probe in measuring cellular iron, there might be a 
degradation mechanism to this probe inside cell, which will limit the iron detection in a small 
period time. In order to solve this, future studies could be done to analyze the degradation 
mechanism and increase the stability of the probe in cells. Furthermore, according to our results, 
the probe reacts with cobalt ions, and it seems that the color of the solution might have a slight 
effect on the fluorescence of the probe.  
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For the studies on the heat shock protein 90 inhibition, cell viability and cellular iron regulation, 
there are a lot more areas needed to be improved. All the unclear areas listed in the section above 
as well as the weaknesses of the studies require further work to provide more insight into how 
heat shock proteins affect iron regulation and cell viability. For example, it is a reasonable 
direction for future studies to determine a direct interaction exists between HSP90 and hepcidin.  
It is also important to determine whether up regulation of HSP70 by HSP90 inhibition has a 
further effect on cell viability. Since our work on HSP90 inhibition was performed using the SH-
SY5Y cell line, in order to get better understanding and far more reliable findings, primary cell 
cultures and even in vivo research should be applied to future studies. Also as a long-term goal, 
there might also be effects of the heat shock proteins on the other metal ions regulation, such as 
potassium and calcium, which also play significant roles in cell viability and activities. Since the 
study of the relationship between heat shock proteins and iron metabolisms is a relatively new 
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